ロード中...

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT

The objective of the SCALE IBT trial (NCT02963935) was to compare the weight loss of liraglutide 3.0 mg, a medication approved by the Food and Drug Administration for chronic weight management, to placebo, both in combination with 56 weeks of intensive behavior therapy (IBT) (i.e. reduced calorie in...

詳細記述

保存先:
書誌詳細
出版年:J Endocr Soc
主要な著者: Shaw Tronieri, Jena, Wadden, Thomas, Sugimoto, Daniel, Lund, Michael, Auerbach, Pernille, Endahl, Lars, Rubino, Domenica
フォーマット: Artigo
言語:Inglês
出版事項: Endocrine Society 2019
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552310/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-097
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!